Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 3166 |
| PDBID: | 6WVZ |
| Chains: | HL_M |
| Organism: | Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 3.10 |
| Reference: | 10.1016/j.jbc.2021.100641 |
| Antibody | |
| Antibody: | amivantamab Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | Amivantamab(Approved) |
| Antigen | |
| Antigen: | Hepatocyte growth factor receptor(mesenchymal-epithelial transition factor (MET) ) |
| Antigen mutation: | No |
| Durg Target: | P08581 |
Sequence information
Antibody
Heavy Chain: H
Mutation: NULL
| >6WVZ_H|Chain A[auth H]|Heavy Chain of anti-MET Fab of amivantamab|Homo sapiens (9606) QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCHHHHHH |
Light Chain: L
Mutation: NULL
| >6WVZ_L|Chain B[auth L]|Light Chain of anti-MET Fab of amivantamab|Homo sapiens (9606) DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Antigen
Chain: M
Mutation: NULL
| >6WVZ_M|Chain C[auth M]|Hepatocyte growth factor receptor|Homo sapiens (9606) MKYQLPNFTAETPIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPEFRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEECLSGTWTQQICLPAHHHHHHHH |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| Chain residues position delta_SASA
: residuesposition H: TYR32 TRP50 SER52 TYR54 ASN55 TYR57 ASN59 ARG98 LEU100 ARG101 GLY102 THR103 ASN104 TYR105 ASP107 L: SER30 ASN31 TRP32 LEU46 TYR49 ALA50 ALA51 SER52 SER53 LEU54 LEU55 SER56 GLY64 SER65 SER67 GLY68 ALA91 ASN92 SER93 PHE94 M: HIS92 PRO93 ASP94 PHE96 PRO97 CYS98 GLN99 ASP100 SER103 LYS104 ALA105 ASN106 ARG143 HIS159 CYS160 PHE162 SER163 PRO164 GLN165 ILE166 GLU167 PRO169 LYS220 THR222 ASP224 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 6 Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 6 Å from any atom.
Interacting residues (Atom distance based)
